[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herombopag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herombopag":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100580565","phase-2-a-clinical-study-on-the-efficacy-and-safety-of-herombopag-in-the-treatment-of-senile-primary-itp-100580565",false,"NCT06838949","A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP","A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary Immune Thrombocytopenia","Inclusion Criteria:\n\n* Patients voluntarily participated in the study and signed informed consent;\n* Age ≥60 years old, gender unlimited;\n* ECOG PS ≤2;\n* Expected survival ≥6 months;\n* A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistent ITP;\n* PLT \\\u003C 30×109\u002FL for at least two consecutive times with an interval of at least 1 day before medication\n* Patients with laboratory test results meet the following criteria: a. alanine aminotransferase (ALT) 3.0 x or less normal limit (ULN), aspartate aminotransferase (AST) 3.0 x ULN or less; b. Serum total bilirubin ≤1.5×ULN; c. Serum creatinine ≤1.5×ULN;\n* The researchers determined that patients could be treated with hexapopal.\n\nExclusion Criteria:\n\n* Patients who did not respond to previous treatment with herombopag;\n* A history of allergy to thrombopoietin receptor agonist (TPO-RA) drugs;\n* Combined with other important organ dysfunction, such as liver and kidney failure, cardiac insufficiency, etc.\n* Secondary thrombocytopenia, such as rheumatic immune disease, chronic liver disease, hyperlienism, malignant hematologic disease, bone marrow hematopoietic exhaustion disease (such as AA, MDS), hereditary thrombocytopenia, CVID, drug-induced thrombocytopenia, etc.;\n* Receive TPO-RA medication within 2 weeks prior to treatment;\n* Non-steroidal anti-inflammatory drugs (aspirin, salicylate, etc.) and anticoagulants (warfarin, clopidogrel, etc.) should be taken during treatment, which have an impact on platelet function.\n* There are severe active bleeding symptoms, such as gastrointestinal bleeding, intracranial bleeding, etc.\n* Severe thrombotic disease, such as transient ischemic attack, myocardial infarction, pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation (DIC), occurred within 6 months prior to the screening period;\n* Have a New York Heart Society (NYHA) Class 3 or 4 congestive heart failure, or have a history of NYHA Class 3\u002F4 congestive heart failure with a left ejection fraction (LVEF) of \\\u003C 45% within 4 weeks prior to treatment;\n* Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody; Hepatitis virus positive, such as HBV, HCV, etc.\n* A history of cirrhosis;\n* Bone marrow reticulum fiber staining (MF) ≥2 grade;\n* Have an active infection that is difficult to control;\n* Have a history of or accompanied by malignant tumors;\n* Pregnant or lactating women;\n* Any other conditions that the investigator determines are not suitable for participation in the study.","ALL","60 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.",[26],"Herombopag","RECRUITING","2025-03-11",{"date":30,"type":31},"2025-03-13","ACTUAL",{"date":33,"type":31},"2025-03-03",{"date":35,"type":20},"2027-12",{"name":37,"class":38},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100457437","phase-2-herombopag-for-chemotherapy-induced-thrombocytopenia-100457437","NCT05236582","Herombopag for Chemotherapy-induced Thrombocytopenia","Herombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors","Inclusion Criteria:\n\n* Aged ≥18 years old, male or female;\n* Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT); Ineffective after repeated treatment with rhTPO or IL-11；\n* Stop radiotherapy or chemotherapy for more than 1 month;\n* Platelet counts \\\u003C30 ×10\\^9\u002FL, and bleeding tendency;\n* Estimated survival period ≥ 6 months；\n* People who are willing to sign the informed consent voluntarily and follow the research program.\n* Liver and kidney function\\\u003C1.5×upper limit of normal, qualified for physical examination；\n* Subject is practicing an acceptable method of contraception. Women of childbearing potential must have a negative serum pregnancy test in the whole study;\n\nExclusion Criteria:\n\n* Those with uncontrollable primary diseases of important organs, such as extensive metastasis of malignant tumors, liver failure, heart failure, kidney failure and other diseases；\n* Patients with poor compliance;\n* Positive serology for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and\u002For hepatitis D virus (HDV), Syphilis; Positive for Epstein-Barr Virus DNA, Cytomegalovirus DNA;\n* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal bleeding, intracranial hemorrhage, etc.\n* There is currently a heart disease requiring treatment or a poorly controlled hypertension judged by the investigator；\n* Patients with thrombotic diseases such as pulmonary embolism, thrombosis, and atherosclerosis；\n* Those who have received allogeneic stem cell transplantation or organ transplantation in the past；\n* Patients with mental disorders who cannot normally obtain informed consent and undergo trials and follow-up；\n* Patients whose toxic symptoms caused by treatment before participating in the trial have not disappeared；\n* Other serious diseases that may restrict participants from participating in this trial (such as diabetes; severe heart failure; myocardial obstruction or unstable arrhythmia or unstable angina in the past 6 months; gastric ulcers; mobility Autoimmune diseases, etc.)；\n* Patients with sepsis or patients with other irregular bleeding；\n* Patients taking antiplatelet drugs at the same time；\n* Pregnant women, suspected pregnancy (a positive pregnancy test for human chorionic gonadotropin in urine at screening) and breastfeeding patients；\n* Pre-existing cardiac disease, including congestive heart failure of New York Heart Association \\[NYHA\\] Grade III\u002FIV, arrhythmia requiring treatment or myocardial infarction within the last 6 months. No arrhythmia known to increase the risk of thrombotic events (e.g. atrial fibrillation), or patients with a QT \\>450msec or QTc \\> 480 for patients with a Bundle Branch Block;\n* Researchers believe that patients should not participate in the test of any other condition.","18 Years",{"count":49,"type":20},50,[23],"To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors",[53,26],"Chemotherapy-induced Thrombocytopenia","2025-02-20",{"date":56,"type":31},"2025-02-24",{"date":58,"type":31},"2022-03-14",{"date":60,"type":20},"2025-12-31",{"name":37,"class":38}]